A conference call with CFDA about GCP implementation
2016-06-13 | Beijing
JY Briefly raised industry concerns regarding while doing clinical trials, requirements for clinical trial executive sites, animal tests, country of origin approval, etc.. Mr. Wu gave preliminary advice to those questions. JY also raised proposal to have a roundtable with the Research and Supervision Division. This needs to be further discussed with WU.